Lupin Limited has inaugurated its new corporate offices in Bridgewater, New Jersey. This expansion underscores Lupin’s commitment to advancing pharmaceutical innovation and supporting the U.S. healthcare system. The new facility will house various corporate functions and enhance Lupin’s operations in the U.S. market. Governor Phil Murphy attended the ribbon-cutting ceremony, highlighting the state’s support for the pharmaceutical industry. Lupin has been in the state since 2016.
New Corporate Hub
Lupin Limited has officially opened its new corporate offices in Bridgewater, New Jersey. The facility at 100 Somerset Corporate Blvd will accommodate multiple corporate functions and consolidate operations within the region. The announcement was made on October 28, 2025.
Strategic Expansion in the U.S.
The new offices span approximately 18,000 square feet and will house commercial, HR, finance, legal, marketing, business development, and R&D functions. This move builds upon Lupin’s existing presence in New Jersey, which includes manufacturing and research facilities in Somerset, and signifies the importance of US operations.
Executive Commentary
Governor Phil Murphy stated that Lupin’s investments in New Jersey are aligned with the state’s priorities of strengthening the pharmaceutical industry, driving economic growth and creating jobs. Vinita Gupta, CEO of Lupin, mentioned that New Jersey is a stronghold for the biopharmaceutical industry and the company has been a member of the community since 2016.
Commitment to Growth
Spiro Garavis, President, U.S. Generics, Lupin, indicated that increasing their presence in New Jersey allows them to scale operations and grow their workforce. The NJ-based workforce now exceeds 300 employees, with plans for further expansion. The company also announced plans to build a state-of-the-art manufacturing facility in Coral Springs, Florida.
Source: BSE
